14 -10 (96) 2026 - Tuxtasinov N.N., Mamatova I.Yu., Ulugbekova G.J. - SURUNKALI RINOSINUSITNING ZAMONAVIY TUSHUNCHALARI

SURUNKALI RINOSINUSITNING ZAMONAVIY TUSHUNCHALARI

Tuxtasinov N.N., Mamatova I.Yu., Ulugbekova G.J. - Andijon davlat tibbiyot instituti

Rezyume

Ushbu maqolada surunkali rinosinusitning zamonaviy tushunchalari, etiologiyasi, patogenezi, klinik xususiyatlari va diagnostikasining dolzarb jihatlari yoritilgan. Kasallik rivojlanishida burun va burun yon bo’shliqlari shilliq qavatidagi surunkali yallig’lanish jarayonlari, immunologik o’zgarishlar hamda turli xavf omillarining o’rni tahlil qilingan. Zamonaviy diagnostika usullari, jumladan, endoskopik tekshiruv va kompyuter tomografiyasining ahamiyati ko’rib chiqilgan. Shuningdek, surunkali rinosinusitni davolashda konservativ va jarrohlik usullariga zamonaviy yondashuvlar, individual davolash strategiyasini tanlash tamoyillari bayon etilgan. Olingan ma’lumotlar kasallikni erta aniqlash, to’g’ri tashxislash va kompleks davolash bemorlarning hayot sifatini yaxshilashda muhim ahamiyatga ega ekanligini ko’rsatadi.

Kalit so’zlar: surunkali rinosinusit, burun bo’shlig’i, burun yon bo’shliqlari, yallig’lanish, diagnostika, endoskopiya, kompyuter tomografiyasi, konservativ davolash, jarrohlik davolash.

First page

101

Last page

109

For citation:Tuxtasinov N.N., Mamatova I.Yu., Ulugbekova G.J. - SURUNKALI RINOSINUSITNING ZAMONAVIY TUSHUNCHALARI//New Day in Medicine 10(96)2026 101-109 https://newdayworldmedicine.com/en/new_day_medicine/10-96-2026

ADABIYOTLAR RO’YXATI

  1. Millares Martin P. New Year, New Challenges for Community Acquired Pneumonia. Arch Bronconeumol. 2017;53(8):469–470. doi: 10.1016/j.arbres.2017.01.013.
  2. Baillat D, Wagner EJ. Integrator: surprisingly diverse functions in gene expression. Trends Biochem Sci. 2015;40(5):257–264. doi: 10.1016/j.tibs.2015.03.005.
  3. Altamura AC, Goikolea JM. Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorder. Neuropsychiatr Dis Treat. 2008;4(1):311–317. doi: 10.2147/ndt.s2703.
  4. Mitri FG. Self-bending scalar and vector bottle sheets. J Opt Soc Am A Opt Image Sci Vis. 2017;34(7):1194–1200. doi: 10.1364/JOSAA.34.001194.
  5. Pagidipati NJ, Navar AM, Mulder H, Sniderman AD, Peterson ED, Pencina MJ. Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. JAMA. 2017;317(15):1563–1567. doi: 10.1001/jama.2017.3416.
  6. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et al. Executive summary of EPOS 2020 including integrated care pathways. Rhinology. 2020;58(2):82–111. doi: 10.4193/Rhin20.601.
  7. Schneider U, Lomax A, Timmermann B. Second cancers in children treated with modern radiotherapy techniques. Radiother Oncol. 2008;89(2):135–140. doi: 10.1016/j.radonc.2008.07.017.
  8. Verma D, Tasan R, Sperk G, Pape HC. Neuropeptide Y2 receptors in anteroventral BNST control remote fear memory depending on extinction training. Neurobiol Learn Mem. 2018;149:144–153. doi: 10.1016/j.nlm.2018.01.011.
  9. Verma D, Wood J, Lach G, Mietzsch M, Weger S, Heilbronn R, et al. NPY Y2 receptors in the central amygdala reduce cued but not contextual fear. Neuropharmacology. 2015;99:665–674. doi: 10.1016/j.neuropharm.2015.08.038.
  10. Kornhuber J, Zoicas I. Valence-dependent effects of neuropeptide Y on the expression of conditioned fear and anxiety-like behavior: Involvement of the bed nucleus of the stria terminalis. Neuropharmacology. 2024;246:109847. doi: 10.1016/j.neuropharm.2024.109847.

    file

    download